Medullary thyroid carcinoma--update and present management controversies

Area of Science:

• Endocrinology
• Oncology
• Genetics

Background:

• Medullary thyroid carcinoma (MTC) is a rare malignancy of thyroid C cells, comprising 5-10% of thyroid cancers.
• MTC presents in sporadic and hereditary forms, with ongoing controversies in diagnosis and management.
• Hereditary MTC is linked to RET protooncogene mutations, often associated with Multiple Endocrine Neoplasia (MEN) syndromes.

Purpose of the Study:

• To address key controversial issues in the diagnosis and management of Medullary Thyroid Carcinoma.
• To review current understanding of MTC genetics, diagnosis, and treatment strategies.
• To highlight the importance of genetic testing and surgical intervention in MTC management.

Main Methods:

• Literature review using the PubMed database.
• Inclusion of original papers cited in identified literature.
• Focus on articles addressing controversial aspects of MTC diagnosis and management.

Main Results:

• Approximately 25% of MTC cases are genetically determined, linked to RET protooncogene mutations.
• Genetic testing identifies at-risk individuals for prophylactic thyroidectomy, improving survival.
• Surgery (total thyroidectomy with nodal dissection) offers the only curative option, achieving biochemical cure in over 80% of primary cases.
• Recurrent or residual disease requires extensive investigation and potentially further surgery, with ~40% achieving calcitonin normalization.

Conclusions:

• Meticulous surgical techniques are crucial for managing MTC.
• Despite surgical advances, MTC has a 10-year survival rate of 60-80%.
• Development of novel medical therapies is anticipated to improve MTC treatment outcomes.